DK0958287T3 - Sulfamidmetalloprotease-inhibitorer - Google Patents

Sulfamidmetalloprotease-inhibitorer

Info

Publication number
DK0958287T3
DK0958287T3 DK98907943T DK98907943T DK0958287T3 DK 0958287 T3 DK0958287 T3 DK 0958287T3 DK 98907943 T DK98907943 T DK 98907943T DK 98907943 T DK98907943 T DK 98907943T DK 0958287 T3 DK0958287 T3 DK 0958287T3
Authority
DK
Denmark
Prior art keywords
sulfamidmetalloprotease
inhibitors
sulfamidmetalloprotease inhibitors
Prior art date
Application number
DK98907943T
Other languages
Danish (da)
English (en)
Inventor
Chris Allen Broka
Jeffrey Allen Campbell
Arlindo Lucas Castelhano
Jian Jeffrey Chen
Robert Than Hendricks
Michael Joseph Melnick
Keith Adrian Murray Walker
Original Assignee
Hoffmann La Roche
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26713422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0958287(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Agouron Pharma filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK0958287T3 publication Critical patent/DK0958287T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Detergent Compositions (AREA)
DK98907943T 1997-01-23 1998-01-14 Sulfamidmetalloprotease-inhibitorer DK0958287T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3671497P 1997-01-23 1997-01-23
US6220997P 1997-10-16 1997-10-16
PCT/EP1998/000180 WO1998032748A1 (fr) 1997-01-23 1998-01-14 Inhibiteurs de sulfamide-metalloprotease

Publications (1)

Publication Number Publication Date
DK0958287T3 true DK0958287T3 (da) 2003-01-20

Family

ID=26713422

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98907943T DK0958287T3 (da) 1997-01-23 1998-01-14 Sulfamidmetalloprotease-inhibitorer

Country Status (35)

Country Link
EP (1) EP0958287B2 (fr)
JP (1) JP3563411B2 (fr)
KR (1) KR100377696B1 (fr)
CN (1) CN1093125C (fr)
AR (1) AR011425A1 (fr)
AT (1) ATE223909T1 (fr)
AU (1) AU730127B2 (fr)
BG (1) BG103586A (fr)
BR (1) BR9807508A (fr)
CA (1) CA2278694C (fr)
DE (2) DE69807845T2 (fr)
DK (1) DK0958287T3 (fr)
EA (1) EA002810B1 (fr)
ES (2) ES2183331T3 (fr)
FR (1) FR2758559A1 (fr)
GB (1) GB2321641B (fr)
HR (1) HRP980036A2 (fr)
HU (1) HUP0000941A3 (fr)
ID (1) ID22849A (fr)
IL (1) IL130802A0 (fr)
IS (1) IS5125A (fr)
IT (1) IT1298163B1 (fr)
MA (1) MA26467A1 (fr)
NO (1) NO313635B1 (fr)
NZ (1) NZ336625A (fr)
OA (1) OA11078A (fr)
PA (1) PA8445301A1 (fr)
PE (1) PE57399A1 (fr)
PL (1) PL334846A1 (fr)
PT (1) PT958287E (fr)
TN (1) TNSN98012A1 (fr)
TR (1) TR199901765T2 (fr)
UY (1) UY24854A1 (fr)
WO (1) WO1998032748A1 (fr)
YU (1) YU34599A (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
HN2000000052A (es) * 1999-05-28 2001-02-02 Pfizer Prod Inc Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos.
EP1187811B1 (fr) 1999-06-04 2007-03-07 AstraZeneca AB Inhibiteurs de metalloproteases
DK1210326T3 (da) 1999-08-18 2004-06-21 Warner Lambert Co Hydroxamsyreforbindelser, der er nyttige som matrixmetalloproteinaseinhibitorer
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
PL365909A1 (en) 2000-02-21 2005-01-10 Astrazeneca Ab Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
JP2003524007A (ja) * 2000-02-21 2003-08-12 アストラゼネカ・アクチエボラーグ アリールピペラジン類およびそれらのメタロプロテイナーゼ阻害剤（ｍｍｐ）としての使用
US6495358B1 (en) * 2000-04-19 2002-12-17 Wichita State University Sulfamide and bis-sulfamide amino acid derivatives as inhibitors of proteolytic enzymes
EP1288199A4 (fr) 2000-04-28 2005-10-12 Shionogi & Co Inhibiteurs de mmp-12
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
US6492171B2 (en) 2000-05-16 2002-12-10 Isis Pharmaceuticals, Inc. Antisense modulation of TERT expression
GB0119474D0 (en) 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
WO2003035610A1 (fr) * 2001-10-26 2003-05-01 Shionogi & Co., Ltd. Derive de sulfonamide a effet inhibiteur sur les mmp
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
CA2479906C (fr) * 2002-04-03 2011-02-08 Topotarget Uk Limited Composes d'acide carbamique comprenant un chainon de piperazine tels que les inhibiteurs hdac
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
EP1511488B1 (fr) 2002-06-12 2013-05-22 Symphony Evolution, Inc. Inhibiteurs humains d'adam 10
EP1493445A1 (fr) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition de l'activation de l'EGFR, cette activation étant dépendante d'un ligand et étant induite par le stress
DE10344936A1 (de) * 2003-09-27 2005-04-21 Aventis Pharma Gmbh Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen
BRPI0510137A (pt) * 2004-05-19 2007-10-02 Solvay Pharm Gmbh medicamentos contendo n-sulfamoil-n'-arilpiperazinas para a profilaxia ou tratamento da obesidade e condições relacionadas
CA2580762A1 (fr) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation comme agents therapeutiques
DE102004060229A1 (de) * 2004-12-15 2006-06-29 Sanofi-Aventis Deutschland Gmbh Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen
US20090069304A1 (en) * 2006-03-03 2009-03-12 Shionogi & Co., Ltd. Mmp-13 selective inhibitor
US20100099676A1 (en) * 2006-11-02 2010-04-22 Shionogi & Co., Ltd. Sulfonylurea derivative capable of selectively inhibiting mmp-13
WO2008147764A1 (fr) * 2007-05-23 2008-12-04 Array Biopharma, Inc. Inhibiteurs des métalloprotéases matricielles (mmp) et leurs méthodes d'utilisation
CN101821233B (zh) * 2007-10-12 2016-06-29 巴斯夫欧洲公司 生产磺酸二酰胺的方法
FR2947268B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
US8431538B2 (en) * 2009-07-22 2013-04-30 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods of using same
KR101913619B1 (ko) * 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Gpr-119의 조절제로서의 신규한 화합물
JP6507267B2 (ja) 2015-05-22 2019-04-24 チョン クン ダン ファーマシューティカル コーポレーション 選択的ヒストンデアセチラーゼ阻害剤としてのヘテロ環状アルキル誘導体化合物及びこれを含有する薬剤学的組成物
EP3860608A1 (fr) 2018-10-04 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibiteurs de l'egfr pour traiter les kératodermies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH617318A5 (en) † 1975-09-30 1980-05-30 Ciba Geigy Ag Microbicidal composition.
US5140009A (en) * 1988-02-10 1992-08-18 Tap Pharmaceuticals, Inc. Octapeptide LHRH antagonists
US5114937A (en) * 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
IE68045B1 (en) * 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
WO1993006127A1 (fr) * 1991-09-17 1993-04-01 Warner-Lambert Company Nouveaux inhibiteurs de renine a base de promedicaments a acides amines
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
HU216747B (hu) † 1994-05-04 1999-08-30 Novartis Ag. Fungicid N-szulfonil- és N-szulfinil-aminosav-amidok, ezek előállítása és alkalmazása, valamint ezeket tartalmazó fungicid készítmények
DE19507447A1 (de) † 1995-03-03 1996-09-05 Vitronic Dr Ing Stein Bildvera Verfahren und Schaltung zum Erfassen und Weiterleiten von Videobilddaten in einem PC
RU2164914C2 (ru) * 1995-11-13 2001-04-10 Хехст Акциенгезелльшафт ЦИКЛИЧЕСКИЕ И ГЕТЕРОЦИКЛИЧЕСКИЕ N-ЗАМЕЩЕННЫЕ α-ИМИНОГИДРОКСАМОВЫЕ И КАРБОНОВЫЕ КИСЛОТЫ
DE69624081T2 (de) * 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix-metalloprotease Inhibitoren
FR2748026B1 (fr) * 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
TR199901765T2 (xx) 1999-10-21
BR9807508A (pt) 2000-03-21
ID22849A (id) 1999-12-09
HRP980036A2 (en) 1998-12-31
DE19802350A1 (de) 1998-07-30
JP3563411B2 (ja) 2004-09-08
TNSN98012A1 (fr) 2005-03-15
FR2758559A1 (fr) 1998-07-24
IS5125A (is) 1999-07-22
ES2183331T3 (es) 2003-03-16
EP0958287B2 (fr) 2008-04-09
NO313635B1 (no) 2002-11-04
OA11078A (en) 2003-03-17
YU34599A (sh) 2002-03-18
DE69807845D1 (de) 2002-10-17
JP2001523222A (ja) 2001-11-20
EP0958287B1 (fr) 2002-09-11
IL130802A0 (en) 2001-01-28
NZ336625A (en) 2001-04-27
GB2321641A (en) 1998-08-05
CA2278694A1 (fr) 1998-07-30
IT1298163B1 (it) 1999-12-20
EP0958287A1 (fr) 1999-11-24
MA26467A1 (fr) 2004-12-20
NO993587D0 (no) 1999-07-22
EA002810B1 (ru) 2002-10-31
HUP0000941A2 (hu) 2001-04-28
NO993587L (no) 1999-09-22
UY24854A1 (es) 2000-12-29
EA199900643A1 (ru) 2000-04-24
DE69807845T2 (de) 2003-06-05
CA2278694C (fr) 2006-09-26
AU730127B2 (en) 2001-02-22
BG103586A (bg) 2000-03-31
WO1998032748A1 (fr) 1998-07-30
HUP0000941A3 (en) 2002-06-28
ES2136037B1 (es) 2000-11-16
CN1250445A (zh) 2000-04-12
CN1093125C (zh) 2002-10-23
AU6614098A (en) 1998-08-18
AR011425A1 (es) 2000-08-16
GB9801393D0 (en) 1998-03-18
PT958287E (pt) 2002-12-31
KR100377696B1 (ko) 2003-03-29
PE57399A1 (es) 1999-06-25
PA8445301A1 (es) 2001-07-31
ATE223909T1 (de) 2002-09-15
KR20000070398A (ko) 2000-11-25
PL334846A1 (en) 2000-03-27
GB2321641B (en) 2001-04-04
ES2136037A1 (es) 1999-11-01
ITMI980091A1 (it) 1999-07-20

Similar Documents

Publication Publication Date Title
DK0958287T3 (da) Sulfamidmetalloprotease-inhibitorer
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
NO20002121D0 (no) Benzotiazol-protein-tyrosin-kinaseinhibitorer
FI963597A7 (fi) Isoprenyylitransferaasi-inhibiittoreita
NO972930D0 (no) Fibronectin-adhesjonsinhibitorer
DK1004669T3 (da) Hidtil ukendte differentieringsinhibitor
FI972160A0 (fi) Matriisimetalloproteaasi-inhibiittorit
NO995433D0 (no) Protease-inhibitorer
DE69835685D1 (de) Mehrtransaktionsmünzgerät
DE69839729D1 (de) Signallisierungsnetzdurchgangssystem
DE69818302D1 (de) Perfusionsverbindungsvorrichtung
DE69840589D1 (de) erungsvorrichtung
DE69834142D1 (de) Tintenzuführsystemadapter
DE19810476B4 (de) Laryngomaske
DE69839459D1 (de) Gehrungssägeschwenklagerfestspannvorrichtung
DE69838649D1 (de) Faltgestellgerät
DE69827636D1 (de) Blutverdünnungsreagenz
NO996578D0 (no) Urokinase-inhibitorer
DE69836021D1 (de) Filteranordung
DE69812610D1 (de) Gurtschlossspanner
NO995435D0 (no) Protease-inhibitorer
NO20003256D0 (no) ACE inhibitor-MMP inhibitor kombinasjoner
NO995434D0 (no) Proteaseinhibitorer
NO995268D0 (no) Proteaseinhibitorer
DE69806297D1 (de) Bilddekodiergerät